Welcome to our dedicated page for Trendlines Group news (Ticker: TRNLY), a resource for investors and traders seeking the latest updates and insights on Trendlines Group stock.
The Trendlines Group ADR (TRNLY) news centers on foreign-issuer and company-related developments involving medical technology, agricultural biotechnology, and sustainable crop-protection businesses. Recurring themes include financing rounds, regulatory clearances, commercial launches, product-development milestones, and governance updates.
Recent updates have referenced IBI Ag's bioinsecticide platform and funding, Arcuro Medical's SuperBall orthopedic technology and FDA clearance, Limaca Medical's Precision-GI endoscopic biopsy device, Escala Medical's pelvic organ prolapse device financing, and EcoPhage's phage-based biopesticide governance activity.
The Bayer Trendlines Ag Innovation Fund has established TierraSpec, a company focused on remote measurement and validation of carbon sequestration in agricultural soil. Utilizing over 30 years of research from Tel Aviv University, TierraSpec aims to provide cost-effective technology for carbon credit issuance and soil health monitoring. This innovation addresses the limited eligibility of agricultural projects for carbon credits, currently at only 1-2%. With a US$10 million investment from Bayer, the initiative supports sustainable agricultural practices and effective carbon reporting.
Escala Medical received FDA clearance for its first pelvic organ prolapse repair device following the successful completion of a one-year follow-up on a first-in-human clinical study involving 17 patients. This device offers a safe, incision-free repair option for women with pelvic organ prolapse, a condition affecting nearly 50% of women globally. Escala's procedure takes less than 10 minutes, enhancing the quality of life for women. Notably, Dr. Mickey Karram joined the Scientific Advisory Board, further strengthening Escala's market position.
Arcuro Medical Ltd. has appointed Dr. Phil Davidson as Medical Director and Dr. Ken Zaslav to its Scientific Advisory Board (SAB). The SAB aims to advance Arcuro's clinical development pipeline, particularly focusing on the SuperBall® Meniscal Repair System, which has successfully treated over 500 patients since receiving FDA approval in June 2018. CEO Lee Ranon emphasized the expertise of the SAB members in enhancing product development and market leadership in meniscal repair devices.
SetBone Medical Ltd., based in Israel, has successfully closed an oversubscribed investment round raising $1.6 million. This funding, backed by notable investors like The Trendlines Group (SGX: 42T) and Agriline, will facilitate the next phase of development and the initiation of a First in Human pilot study. SetBone's innovative bone cement addresses limitations in current orthopedic solutions and aims to capture a share of the projected $1.4 billion bone cement market by 2028, targeting conditions like Vertebral Compression Fractures.
The Trendlines Group Ltd. has invested in AgriG8 Pte Ltd., marking its entry into the agri-fintech sector. AgriG8 aims to enhance access to financing for smallholder farmers, a critical segment in global agriculture. Utilizing big data and AI, the platform encourages farmers towards sustainable practices, altering borrowing rates based on behavior. The initiative plans to pilot its services in Q1 2022 and expand into Africa and Indonesia by Q3 2022. Trendlines acknowledges the significant gap in financing for small farmers and believes AgriG8's approach is innovative and beneficial.
FruitSpec has completed a $5 million investment round led by Amathaon Capital, Ocean Azul, and Smart Agro. The funding will enhance their Yield Management Platform, which improves fruit supply-chain management through accurate yield predictions and digital tools. This platform addresses operational inefficiencies and aims to increase profitability within the $5.4 billion US fresh produce market. CEO Raviv Kula emphasizes the global expansion efforts with this funding, highlighting growth opportunities in markets like Chile, the US, South Africa, and Spain.
Vensica Therapeutics, a clinical-stage biopharmaceutical company based in Israel, announced a successful investment round, closing $16 million. The round was led by Israel Biotech Fund and included notable investors such as Laborie and The Trendlines Group. The funds will support Vensica's phase II clinical trials in the US and Europe, focusing on its needle-free ultrasound-assisted drug delivery platform for treating urological conditions like overactive bladder. CEO Avner Geva expressed optimism for innovative treatment solutions in bladder diseases, while the company plans to expand its workforce in Israel.
Fidmi Medical Ltd., based in Israel, has successfully completed a $2.2 million financing round and launched its FDA-cleared low-profile Percutaneous Endoscopic Gastrostomy (PEG) device in the U.S. The financing round included notable investors such as Micro-Tech Co., Ltd. and The Trendlines Group. This innovative gastrostomy device, designed for long-term nutritional support, targets a market worth $800 million. Its replaceable inner tube and stable internal bumper aim to reduce complications and healthcare costs, enhancing patient quality of life.
Röchling Medical and Trendlines Innovation Labs announced a collaboration on Oct. 6, 2021, to enhance medical device innovation and manufacturing. The partnership aims to create a comprehensive solution for product development in the healthcare industry, leveraging Röchling's expertise in manufacturing and Trendlines' strengths in R&D. Röchling Medical has a proven track record in the life sciences, while Trendlines focuses on early-stage development of medical technologies. This collaboration seeks to improve health outcomes globally by addressing critical unmet needs.
CoreBone, based in Tel Aviv, Israel, has announced a successful investment round, raising $3.7 million. The investment includes $3 million from the Guangzhou Sino-Israel Biotech Investment Fund for its Chinese subsidiary, alongside $700,000 from The Trendlines Group and Agriline. This funding will facilitate the expansion of CoreBone's bioactive, coral-based bone graft materials into the rapidly growing Chinese market, which bans the import of foreign human-derived grafts, thus presenting a unique opportunity for CoreBone's products.